- Home
- NVVE vs APRE Comparison
NVVE vs APRE Comparison
Compare NVVE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVVE | APRE |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 6.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NVVE | APRE |
|---|---|---|
| Price | $3.46 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 240.8K | 82.4K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,630,156.00 | $488,239.00 |
| Revenue This Year | $892.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.84 |
| 52 Week High | $200.80 | $4.65 |
Technical Indicators
Market Signals| Indicator | NVVE | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 42.01 |
| Support Level | $1.98 | $0.91 |
| Resistance Level | $4.14 | $1.00 |
| Average True Range (ATR) | 0.52 | 0.06 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 63.22 | 46.67 |
Price Performance
Historical ComparisonAbout NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.